City Therapeutics Inc. has completed a $99.5 million series B financing to support its pipeline of RNA interference (RNAi) therapeutics and accelerate its next-generation RNAi engineering platform.
Total biopharma financing through the first five months of 2026 reached $49.46 billion, the third-highest total for the period in the dataset and more than doubling of 2025’s $21.4 billion over the same stretch.
Artan Biotechnologies LLC has completed a $200,000 seed raise to fund preclinical advancement of the company’s proprietary engineered suppressor platform, which targets nonsense mutations.
Biopharma and med-tech companies raising money in public or private financings, including: Advanced Nanotherapies, Bluejay, Liminatus, Lixte, Medtronic, Mineralys, Nrx.
Antibody-drug conjugate (ADC) specialist Ona Therapeutics SL has closed an oversubscribed series B at $86.6 million, as clinical development of the lead program ONA-255 in advanced treatment-resistant breast cancer gathers steam.
Idefine, The Kleefstra Syndrome Foundation, has established a collaboration with UT Southwestern Medical Center to advance development of a potential gene therapy to treat Kleefstra syndrome, a rare neurodevelopmental disorder caused by changes or loss of the EHMT1 gene, which plays a critical role in brain development and function.
The Coalition for Epidemic Preparedness Innovations (CEPI) will provide up to $9.7 million in additional funding to Pop Biotechnologies Inc. to advance the company’s Pop Bio SNAP (Spontaneous Nanoliposome Antigen Particle) protein vaccine platform into a phase I trial.
RSS
